Intrarosa EMA vs FDA Approach: What Every Woman Should Know

What Is Intrarosa and Why Does Regulatory Framing Matter for You?

Intrarosa is a once-nightly vaginal insert containing 6.5 mg of prasterone, the synthetic form of dehydroepiandrosterone (DHEA). Inside vaginal epithelial cells, DHEA converts locally into estrogens and androgens through intracrinology, meaning the hormones act primarily at the tissue level rather than flooding the bloodstream. That local-conversion mechanism is central to why the FDA and the European Medicines Agency approached this drug so differently, and why the label language you read in the package insert may not match what you find on an EU patient information leaflet.

For women living with genitourinary syndrome of menopause (GSM), the regulatory story matters in a practical way: the indication wording, the safety warnings, and the post-market surveillance obligations differ between the two agencies. Understanding those differences helps you have a better-informed conversation with your clinician about whether this is the right choice for your life stage and your symptom picture.

GSM affects an estimated 45 percent of postmenopausal women and includes vaginal dryness, irritation, painful sex, urinary urgency, and recurrent infections. Unlike vasomotor symptoms, GSM does not improve without treatment.

The FDA Approval: NDA 208470 and What the Label Actually Says

Approval Date and Indication

The FDA approved Intrarosa on November 17, 2016 under NDA 208470. The approved indication is narrow and specific: treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. Dyspareunia means painful intercourse. The FDA did not approve prasterone for vaginal dryness as a standalone indication or for the broader GSM symptom cluster, which is a notable restriction compared to what the EMA later approved.

The Key Trial: Labrie 2016

The FDA's approval rested heavily on the phase 3 randomized controlled trial published by Labrie et al. In Menopause (2016). That trial enrolled 422 postmenopausal women with moderate-to-severe dyspareunia and most bothersome symptom criteria. Participants received prasterone 6.5 mg or placebo vaginally each night for 12 weeks. The prasterone group showed statistically significant improvements in four co-primary endpoints: percentage of superficial cells on vaginal smear, percentage of parabasal cells, vaginal pH, and the severity score for the most bothersome symptom. The mean improvement in dyspareunia severity was 1.42 points on a 0-3 scale versus 1.05 for placebo, a statistically significant difference with a p-value below 0.001.

Systemic Hormone Exposure: The FDA's Cautious Language

The FDA label addresses systemic absorption directly. Serum DHEA, testosterone, estradiol, and estrone levels rose measurably during treatment but remained within the normal postmenopausal range according to the FDA prescribing information. The agency did not add a black-box warning for breast cancer or endometrial cancer, but it did include a precaution stating that long-term endometrial safety has not been studied beyond 52 weeks. The label also notes that the drug has not been studied in women with a history of hormone-sensitive cancer, and clinical judgment is required before prescribing to that population.

Post-Market Surveillance Commitment

The FDA required Prasterone sponsor Millicent (formerly AMAG, formerly Endoceutics in original development) to complete a post-approval study on endometrial safety. That commitment reflects the agency's standard practice for any product with measurable systemic estrogen exposure, even when levels stay within the postmenopausal reference range. As of the most recent FDA Sentinel update available, that long-term study remains ongoing.

The EMA Approval: EU/1/19/1444 and How It Differs

Later Approval, Broader Indication

The EMA granted marketing authorization to Intrarosa in March 2020 under authorization number EU/1/19/1444, roughly three and a half years after the FDA. The European label covers a broader indication: treatment of symptoms of vulvovaginal atrophy in postmenopausal women. That wording captures vaginal dryness, itching, and irritation, not only dyspareunia, which aligns Intrarosa more closely with other vaginal estrogen products in European practice.

Different Framing of the Hormone-Conversion Mechanism

The EMA's European Public Assessment Report (EPAR) explicitly acknowledges the intracrine mechanism and frames the drug as acting through local androgen and estrogen production without clinically meaningful systemic exposure in healthy postmenopausal women. The EPAR language is notably less hedged than the FDA prescribing information on this point. European regulators concluded that the measurable serum hormone increments do not constitute systemic hormonal therapy and therefore declined to apply the HRT-class warnings seen on systemic estrogen products.

The FDA, by contrast, included language noting that the clinical relevance of the observed serum hormone changes is unknown, which is a more conservative framing of the same pharmacokinetic data.

What the Two Labels Agree On

Both agencies agree on the core pharmacology, the 12-week efficacy data, the once-nightly 6.5 mg dose, and the postmenopausal-only population. Both label the drug as contraindicated in women with unexplained vaginal bleeding and advise evaluation before use. Both confirm that no meaningful endometrial proliferation was seen in the 12-week trials, though neither has long-term data beyond 52 weeks.

Sex-Specific Physiology: Why This Drug Works the Way It Does in Postmenopausal Women

DHEA is the most abundant circulating steroid in premenopausal women, peaking in the mid-20s and declining steadily with age. By the late postmenopause, circulating DHEA-S (the sulfated storage form) has fallen by approximately 60 to 80 percent from peak levels. Vaginal epithelial cells express the full complement of steroidogenic enzymes needed to convert DHEA locally into both androgens (testosterone, dihydrotestosterone) and estrogens (estradiol, estrone).

This is not how oral or transdermal hormone therapy works. Systemic HRT delivers hormones directly into the bloodstream, where they reach every tissue simultaneously. Prasterone delivers a precursor molecule to vaginal tissue, where local enzymes drive conversion at concentrations that reflect the tissue's own enzymatic capacity. That distinction explains why the serum hormone increments seen with Intrarosa are small and why both the FDA and EMA agreed that progesterone co-administration (to protect the endometrium) is not required, unlike with vaginal estrogen products that can occasionally produce systemic absorption at higher doses.

How the Menstrual Cycle and Hormonal Status Change the Picture

Intrarosa carries a postmenopausal-only indication. In premenopausal women, baseline DHEA levels are higher, the endometrium is still responsive to estrogen, and the clinical rationale for vaginal DHEA is far less established. Women in late perimenopause with significant GSM symptoms but irregular periods are not included in the key trial populations, so use in this group is off-label. If you are perimenopausal and considering this drug, discuss with your clinician whether you meet a reasonable definition of the postmenopausal state (typically 12 consecutive months without a period, or FSH confirmation in the context of a hysterectomy).

Androgen Receptor Activity and Female Sexual Function

The local androgen component of prasterone's action matters for women beyond lubrication. Androgen receptors in vaginal smooth muscle and the labia contribute to arousal, engorgement, and orgasmic function. The Labrie 2016 trial reported improvements in sexual desire, arousal, lubrication, and satisfaction scores alongside the structural vaginal changes. This dual androgenic-estrogenic mechanism is what distinguishes prasterone from low-dose vaginal estrogen products, which act almost entirely through estrogen receptors. No head-to-head trial has compared prasterone directly to vaginal estradiol tablets or the vaginal estradiol ring for dyspareunia, so the claim that it is "superior" to vaginal estrogen lacks direct evidence.

Female-Relevant Conditions: PCOS, Breast Cancer History, and Beyond

PCOS and Androgen Sensitivity

Women with polycystic ovary syndrome have higher baseline androgen levels and sometimes elevated DHEA-S. While prasterone is a postmenopausal drug and most PCOS-affected women are premenopausal, some women carry PCOS into the perimenopause and menopause transition. The FDA label does not address PCOS-related androgen status. No trial has evaluated prasterone in postmenopausal women with a PCOS background, and the theoretical concern that additional androgen precursor load could be additive in women with residual hyperandrogenism is unaddressed in the published literature. Clinicians should use caution in this subgroup.

Hormone-Sensitive Cancer History

The FDA prescribing information explicitly states that Intrarosa has not been studied in women with a history of breast cancer. The 2023 ACOG Clinical Practice Bulletin on GSM notes that for women with hormone-sensitive cancer histories, non-hormonal vaginal moisturizers and lubricants are the first-line recommendation, and any hormonal or hormone-precursor vaginal product should be discussed with the treating oncologist. Prasterone's local conversion to estradiol, even at low serum levels, remains a theoretical concern for estrogen-receptor-positive breast cancer survivors, though no trial has demonstrated harm in this population. The evidence gap here is real, and the honest answer is that the data simply do not exist to call it safe in that group.

Endometriosis and Uterine Fibroids

Both conditions are estrogen-sensitive. Because prasterone generates some local-to-systemic estrogen, the same caution applies. No trial has enrolled women with active endometriosis or significant fibroids. Postmenopausal women whose endometriosis was not surgically excised may warrant discussion with a specialist before starting prasterone.

Female Pattern Hair Loss

Prasterone increases local androgen availability. Whether systemic spillover is sufficient to influence scalp follicle androgen sensitivity is unknown. Women with androgenetic alopecia who are considering Intrarosa should raise this with their dermatologist, as no formal study addresses the interaction.

Pregnancy, Lactation, and Contraception

Pregnancy: Contraindicated

Intrarosa is approved exclusively for postmenopausal women. There is no pregnancy category assigned under the legacy FDA ABCDX system because the drug was approved after the FDA's 2015 switch to the Pregnancy and Lactation Labeling Rule (PLLR). Under PLLR, the label states that there are no human data on use during pregnancy and that the drug is not indicated for use in women who are or may become pregnant. DHEA has androgenic activity. Fetal exposure to androgens during organogenesis carries a theoretical risk of virilization of a female fetus, by analogy with known androgen teratogenicity, though this has not been studied for vaginal prasterone specifically.

If a woman using Intrarosa has any uterine tissue and any possibility of ovarian function (i.e., she is not clearly postmenopausal), pregnancy should be excluded before starting therapy. The drug is not a contraceptive.

Lactation: Not Recommended

No human lactation pharmacokinetic data exist for vaginal prasterone. DHEA and its steroid metabolites are lipophilic and could theoretically transfer into breast milk, but concentrations and infant dose have never been measured. Because the approved indication is postmenopausal, lactation is not a likely scenario, but any woman who is postpartum and has reached menopause early for medical reasons should be counseled that data are absent.

Contraception Requirements

Prasterone is not a teratogen in the strict regulatory sense, but because it converts to estrogens and androgens and because GSM in a woman who still has ovarian function would be off-label use, reliable contraception is appropriate if any reproductive potential exists. The drug is not classified as requiring a REMS or mandatory contraception program, unlike true teratogens such as isotretinoin or thalidomide.

Who Is This Right For, and Who Should Pause

Life Stages Where Intrarosa Fits

Intrarosa is most clearly appropriate for postmenopausal women (12-plus consecutive months without a menstrual period, confirmed by clinical assessment or hormone levels) who have moderate-to-severe dyspareunia as their primary GSM symptom and who are not using systemic HRT. Women who cannot tolerate systemic estrogen for personal, oncologic, or cardiovascular reasons may find this drug attractive precisely because the local mechanism limits systemic exposure, though the absence of long-term data beyond 52 weeks should be part of the informed-consent conversation.

The Menopause Society (formerly NAMS) 2023 position statement on non-estrogen therapies for GSM supports vaginal prasterone as an effective option with a distinct mechanism from vaginal estrogens.

Life Stages and Situations Where You Should Wait or Discuss Further

• Perimenopause with irregular cycles: off-label, discuss FSH and cycle history with clinician before starting.
• Breast cancer survivors on aromatase inhibitors: the local estrogen conversion is a real concern; discuss with your oncologist.
• Women with PCOS and residual hyperandrogenism entering menopause: no data exist; individual assessment needed.
• Women with unexplained vaginal bleeding: both FDA and EMA label this a contraindication pending evaluation.
• Women with active endometriosis: insufficient data.

Comparing the FDA and EMA Regulatory Philosophies on Prasterone

The FDA's approach is characteristically risk-conservative on systemic hormone exposure. The agency required the sponsor to demonstrate that serum hormone levels stayed within postmenopausal norms, included precautionary language about the unknown long-term clinical relevance of even small hormonal rises, and mandated a post-approval endometrial safety study.

The EMA, working from the same clinical dataset, emphasized the intracrine mechanism as the defining pharmacological feature. European regulators concluded that the absence of systemic hormonal effect was itself the key safety finding, not merely an uncertain signal. This led to broader indication language and a product information leaflet that explicitly differentiates prasterone from systemic HRT.

Dr. Elena Vasquez, WomanRx Editorial Board (OB-GYN, NAMS-certified menopause practitioner), summarizes the clinical consequence: "The FDA label puts a woman and her prescriber in the position of interpreting cautious language that does not fully reflect what the pharmacokinetic data actually show. The EMA language is closer to the scientific consensus on intracrinology. Neither label is wrong, but a woman reading the FDA prescribing information without context may conclude this drug is more systemically active than the evidence suggests it is."

For women in the US, the practical implication is that some clinicians may be hesitant to prescribe Intrarosa to women with a hormone-sensitive cancer history based on the hedged FDA label language, even though the EMA concluded systemic exposure is not clinically meaningful. That regulatory gap translates directly into access differences.

What to Expect Clinically: Dose, Timeline, and Monitoring

Intrarosa comes as a single-dose applicator containing the 6.5 mg prasterone vaginal insert. You insert one applicator vaginally at bedtime each night. There is no every-other-day or weekly dosing schedule; nightly use is the studied regimen. Missing occasional nights is unlikely to be clinically significant, but no intermittent dosing trial has been conducted.

Symptom improvement in the key trial was measurable at 4 weeks and statistically strong at 12 weeks. Structural changes to the vaginal epithelium (parabasal cell reduction, pH normalization) were confirmed at 12 weeks. Most women notice reduced dryness within 4 to 6 weeks and improvement in dyspareunia within 8 to 12 weeks.

Monitoring beyond symptom assessment is not specifically mandated by either the FDA or EMA label. However, given the open question about long-term endometrial safety, any postmenopausal woman who develops unexpected vaginal bleeding while using Intrarosa should stop the drug and seek evaluation to exclude endometrial pathology.

Serum hormone monitoring (DHEA-S, testosterone, estradiol) is not routinely recommended by the FDA label and is not standard clinical practice. If you are already on testosterone therapy for hypoactive sexual desire disorder (HSDD) and considering adding vaginal prasterone, discuss the additive androgen load with your prescriber, as no data exist on combined use.

Evidence Gaps Women Deserve to Know About

Women have been historically under-represented in clinical trials. For prasterone, the key trial populations were majority white and postmenopausal; data in women of color, women with surgical menopause at younger ages, women on aromatase inhibitors, and women with prior pelvic radiation are sparse to nonexistent. The 52-week open-label extension provides the longest safety window available, but gynecologic oncologists and breast oncologists rightly note that estrogen-receptor-positive cancer survivors who are their patients were excluded from these studies.

The evidence base for prasterone is stronger than for many newer vaginal products, but the honest clinical picture is that we have strong 12-week efficacy data, reasonable 52-week safety data, and no randomized controlled trial beyond one year. The FDA post-market endometrial safety study will be the most important piece of future evidence for longer-term users.